quisinostat development code experimental drug candidate treatment cancer second generation histone deacetylase inhibitor antineoplastic highly potent class ii developed janssen pharmaceuticals licensed newvac preclinical studies show quisinostat amplifies hdacrepressed expression ecadherin leading reversal epithelial mesenchymal transition tumor results phase trials patients multiple myeloma combination bortezomib dexamethasone published antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikiquisinostat